EligibleTrials

Application of ihMT MRI in Multiple Sclerosis

Recruiting · NCT03600779 · Interventional (participants receive a specific treatment) · Lead sponsor: Assistance Publique Hopitaux De Marseille

View the official record on ClinicalTrials.gov →
Multiple sclerosis

Interventions studied

inhomogeneous Magnetisation Transfer (ihMT) sequenceinhomogeneous Magnetisation Transfer (ihMT) sequence at 3T

What this trial is about

The development of in vivo biomarkers sensitive to myelin disruption represents a major clinical need to be able to monitor the demyelination processes as well as the effect of remyelinating therapies in multiple sclerosis. The investigators recently proposed a technique, derived from the conventional magnetisation transfer (MT): inhomogeneous Magnetisation Transfer (ihMT). In preliminary studies, this simple-to-implement and robust technique has shown great sensitivity for evaluating the demyelination processes. The goal of the project is to evaluate the ability of ihMT to measure and describe the spontaneous demyelination and remyelination processes involved in active lesions in a population of patients with MS at the the disease onset.

Who can take part

Age range
18 Years to 45 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.